Liquidia Announces Presentations at the 2022 American Thoracic Society (ATS) International Conference
May 16 2022 - 6:30AM
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”)
today announced the presentation of data related to the
investigational use of YUTREPIA™ (treprostinil) inhalation powder,
previously referred to as LIQ861, at the America Thoracic Society
(ATS) International Conference 2022 in San Francisco, California.
Mini-symposium: Sunday, May 15 - Safety and Tolerability of
LIQ861 in Pulmonary Arterial Hypertension (PAH): Results from
INSPIRE Study. Presented by Nicholas P. Hill, M.D., Tufts Medical
Center, Boston, Massachusetts.
Thematic poster session: Monday, May 16 - Safety and
Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH):
Results from INSPIRE Study. Presented by Nicholas P. Hill, M.D.,
Tufts Medical Center, Boston, Massachusetts.
Copies of the presentations are available on the Company’s
website at http://liquidia.com/print-technology/publications/.
About YUTREPIA™ (treprostinil) inhalation
powderYUTREPIA is an investigational, inhaled dry powder
formulation of treprostinil delivered through a proven, convenient,
palm-sized device. On November 5, 2021, the FDA issued a tentative
approval for YUTREPIA, which is indicated for the treatment of
pulmonary arterial hypertension (PAH) to improve exercise ability
in adult patients with New York Heart Association (NYHA) Functional
Class II-III symptoms. YUTREPIA was designed using Liquidia’s
PRINT® technology, which enables the development of drug particles
that are precise and uniform in size, shape, and composition, and
that are engineered for optimal deposition in the lung following
oral inhalation. Liquidia has completed INSPIRE, or Investigation
of the Safety and Pharmacology of Dry Powder Inhalation of
Treprostinil, an open-label, multi-center phase 3 clinical study of
YUTREPIA in patients diagnosed with PAH who are naïve to inhaled
treprostinil or who are transitioning from Tyvaso (nebulized
treprostinil). YUTREPIA was previously referred to as LIQ861 in
investigational studies.
About Liquidia CorporationLiquidia
Corporation is a biopharmaceutical company focused on the
development and commercialization of products in pulmonary
hypertension and other applications of its PRINT® Technology. The
company operates through its two wholly owned subsidiaries,
Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia
Technologies has developed YUTREPIA™ (treprostinil) inhalation
powder for the treatment of pulmonary arterial hypertension (PAH).
Liquidia PAH provides the commercialization for pharmaceutical
products to treat pulmonary disease, such as generic Treprostinil
Injection. For more information, please visit www.liquidia.com.
Forward-Looking StatementsThis press release
may include forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Liquidia cautions
readers that forward-looking statements are based on management's
expectations and assumptions as of the date of this news release
and are subject to certain risks and uncertainties that could cause
actual results to differ materially, including, but not limited to,
the impact of the coronavirus (COVID-19) pandemic on our Company
and our financial condition and results of operations; and other
risks and uncertainties identified in the Company's filings with
the U.S. Securities and Exchange Commission. Forward-looking
statements reflect our analysis only on their stated date, and
Liquidia takes no obligation to update or revise these statements
except as may be required by law.
Contact Information for Media &
InvestorsJason AdairSenior Vice President, Corporate
Development and Strategy919.328.4400jason.adair@liquidia.com
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Apr 2024 to May 2024
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From May 2023 to May 2024